Cargando…

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review

Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disease remission is a potential goal of urate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabi-Amponsah, Adwoa Dansoa, Stewart, Sarah, Hosie, Graham, Stamp, Lisa K., Taylor, William J., Dalbeth, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304712/ https://www.ncbi.nlm.nih.gov/pubmed/37375727 http://dx.doi.org/10.3390/ph16060779

Ejemplares similares

The Patient Experience of Gout Remission: A Qualitative Study
por: Tabi‐Amponsah, Adwoa Dansoa, et al.
Publicado: (2023)

The relationship between ferritin and urate levels and risk of gout
por: Fatima, Tahzeeb, et al.
Publicado: (2018)

Is repeat serum urate testing superior to a single test to predict incident gout over time?
por: Stewart, Sarah, et al.
Publicado: (2022)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis
por: Robinson, Philip C., et al.
Publicado: (2021)

Interventions to improve uptake of urate-lowering therapy in patients with gout: a systematic review
por: Gill, Iqbal, et al.
Publicado: (2020)

When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
por: Choi, Hyon K., et al.
Publicado: (2022)

Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank
por: Narang, Ravi K., et al.
Publicado: (2019)

Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis
por: Morillon, Melanie B, et al.
Publicado: (2016)

Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout
por: Dalbeth, Nicola, et al.
Publicado: (2015)

Urate crystal deposition and bone erosion in gout: ‘inside-out’ or ‘outside-in’? A dual-energy computed tomography study
por: Towiwat, Patapong, et al.
Publicado: (2016)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares
por: Flynn, Tanya J, et al.
Publicado: (2015)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

The genetics of gout: towards personalised medicine?
por: Dalbeth, Nicola, et al.
Publicado: (2017)

The renal urate transporter SLC17A1 locus: confirmation of association with gout
por: Hollis-Moffatt, Jade E, et al.
Publicado: (2012)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Effect of omega-three supplementation on serum urate and gout flares in people with gout; a pilot randomized trial
por: Stamp, Lisa K., et al.
Publicado: (2022)

Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout
por: Batt, Caitlin, et al.
Publicado: (2014)

Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol
por: Ofanoa, Malakai, et al.
Publicado: (2021)

The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
por: Hoque, Kazi Mirajul, et al.
Publicado: (2020)

Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
por: Dalbeth, Nicola, et al.
Publicado: (2018)

Inequities in people with gout: a focus on Māori (Indigenous People) of Aotearoa New Zealand
por: Te Karu, Leanne, et al.
Publicado: (2021)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations
por: Stewart, Sarah, et al.
Publicado: (2016)

Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects
por: Flynn, Tanya J, et al.
Publicado: (2013)

Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate‐Lowering Response—In Search of a Minimum Effective Oxypurinol Concentration
por: Stamp, Lisa K., et al.
Publicado: (2019)

Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout
por: Rasheed, Humaira, et al.
Publicado: (2017)

The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics
por: Hishe, Hailemichael Z., et al.
Publicado: (2022)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Urate-lowering treatment and risk of total joint replacement in patients with gout
por: Kuo, Chang-Fu, et al.
Publicado: (2018)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study
por: Uhlig, Till, et al.
Publicado: (2021)

Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge
por: Dalbeth, Nicola, et al.
Publicado: (2014)

The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial
por: Stamp, Lisa K., et al.
Publicado: (2017)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort
por: Ranieri, Laura, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jfh5ptficka2j0t9gmm63hqtj0